



SOCIETÀ ITALIANA DI CANCEROLOGIA

MISSION POSSIBLE



understanding cancer-host dialogues
for personalized cancer medicine

Bologna, 1-4 October 2012
Istituto Ortopedico Rizzoli

**54th Annual Meeting of the
Italian Cancer Society**



SERVIZIO SANITARIO REGIONALE
EMILIA - ROMAGNA
Istituto Ortopedico Rizzoli di Bologna
Istituto di Ricovero e Cura a Carattere Scientifico





WELCOME LETTER

Dear Members of SIC, Colleagues and Friends,

It is our great pleasure to invite you to Bologna for the 54th Meeting of the Italian Cancer Society, SIC, to be held October 1-4, 2012. As always, the SIC Meeting will gather Italian scientists active in all major areas of cancer research who wish to present their new findings and to interact with Italian colleagues and distinguished International guests.

“Mission [im]possible”, the title of the 2012 Meeting, echoing the famous series of action movies, stresses the challenges of researchers, not only to devise novel cures for highly malignant cancers, but also to ensure the effective translation from promising preclinical results to effective clinical approaches. We are confident that the novel results and ideas to be presented at the Meeting will significantly contribute to remove the prefix [im] from [im]possible.

The backbone of the meeting will be symposia, lectures, oral presentation sessions and poster discussions, covering the most exciting topics in basic, translational, and clinical research. Traditional SIC events will be the joint SIC-AIOM session and the “Giorgio Prodi” memorial lecture, awarded to an internationally recognized Italian investigator. We are indebted to members of the Local Scientific Committee and of the SIC Board who shaped a fresh and exciting scientific programme.

Young investigators are especially invited to participate also taking advantage of the many dedicated initiatives, including a two-hour pre-meeting that this year will be dedicated to discuss challenges in obtaining research grants, “Piero Trivella” and EACR Prizes for best posters, the “Elena Cappannini” Award for the best publication, and the Pezcoller Foundation scholarship.

The Meeting venue will be the Rizzoli Orthopaedic Institute, a scientific healthcare institution that comprises treatment and research. Founded in 1896, in the monastic complex of San Michele in Bosco on the hill close to the Bologna center it offers visitors the opportunity of admiring its fascinating architecture, frescos and other works of art from the XVI and XVII centuries.

We look forward to welcoming you all in Bologna!

Katia Scotlandi
Scientific Coordinator

Riccardo Dolcetti
SIC President

Guido Biasco
Scientific Coordinator

MISSION IMPOSSIBLE



understanding cancer-host dialogues
for personalized cancer medicine

Bologna, 1-4 October 2012
Istituto Ortopedico Rizzoli

54th Annual Meeting of the Italian Cancer Society

Under the high patronage of the
PRESIDENT OF THE ITALIAN REPUBLIC

with the auspices of





A grateful thank to:

**Novartis Oncology
Takeda**

**Astrazeneca
Boeringher Ingelheim
Fondazione Mafalda Righi
Igea
M-Medical
Merck Millipore
Pfizer Italia
PharmaMar
Roche Applied Sciences
Tecniplast**

**Eisai
Euroclone
Leica
Life Technologies
Lonza Bioscience
Merck Serono
Nikon
Partec
Prodotti Gianni
Qiagen
Sigma Aldrich
Space Import Export
Tema Ricerca
Vinci-Biochem**



SIC SCIENTIFIC BOARD

President

Riccardo Dolcetti (*CRO-IRCCS, National Cancer Institute, Aviano, Pordenone, Italy*)

President Elect

Silvia Giordano (*Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy*)

Board

Anna Bagnato (*Regina Elena National Cancer Institute, Rome, Italy*)

Vincenzo Bronte (*University of Verona, Italy*)

Maurizio D'Incalci (*"Mario Negri" Institute for Pharmacological Research, Milan, Italy*)

Nicola Normanno (*"G. Pascale" National Cancer Institute, Naples, Italy*)

Salvatore Pece (*IFOM-IEO Campus, Milan, Italy*)

Katia Scotlandi (*IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy*)

Gabriella Sozzi (*IRCCS National Cancer Institute, Milan, Italy*)

Stefania Tommasi (*"Giovanni Paolo II" National Cancer Institute, Bari, Italy*)

Giuseppe Viglietto (*University of "Magna Graecia", Catanzaro, Italy*)

Past President

Alfredo Fusco (*Institute of Endocrinology and Experimental Oncology, CNR, Naples, Italy*)

Representative for Young Researchers

Chiara Gabellini (*Regina Elena National Cancer Institute, Rome, Italy*)

Pierlorenzo Pallante (*Institute of Endocrinology and Experimental Oncology, CNR, Naples, Italy*)

SCIENTIFIC AND ORGANIZING COMMITTEE

Scientific Coordinators

Katia Scotlandi (*IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy*)

Guido Biasco (*University of Bologna, Italy*)

Local Scientific Committee

Michele Baccarani (*University of Bologna, Italy*)

Lucio Cocco (*University of Bologna, Italy*)

Sandro Grilli (*University of Bologna, Italy*)

Pier-Luigi Lollini (*University of Bologna, Italy*)

Andrea Pession (*University of Bologna, Italy*)

Piero Picci (*IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy*)

Stefano A. Pileri (*University of Bologna, Italy*)

SIC SECRETARIAT

Società Italiana di Cancerologia

Via G. Venezian, 1 - 20133 Milan, Italy

Ph. +39 02 2666895

Fax +39 02 2664342

E-mail: sic@istitutotumori.mi.it

Web site: www.cancerologia.it

ORGANIZING SECRETARIAT

Studio E.R. Congressi - Triumph Group

Via Marconi, 36 - 40122 Bologna, Italy

Ph. +39 051 4210559

Fax +39 051 4210174

E-mail: ercongressi@triumphgroup.it

Web site: www.ercongressi.it



FACULTY

Fernando Aguilar

ANSES, National Agency of Health Security,
Maisons-Alfort Cedex, France

Lucia Altucci

“Second” University of Naples, Italy

Anna Bagnato

Regina Elena National Cancer Institute, Rome, Italy

Gustavo Baldassarre

CRO-IRCCS, National Cancer Institute, Aviano,
Pordenone, Italy

Alberto Bardelli

Institute for Cancer Research and Treatment,
University of Turin, Candiolo, Italy

Antonino Belfiore

University of “Magna Graecia”, Catanzaro, Italy

Guido Biasco

University of Bologna, Italy

Alfredo Budillon

“G. Pascale” National Cancer Institute, Naples, Italy

Mario P. Colombo

IRCCS National Cancer Institute, Milan, Italy

Pietro Comba

ISS, Institute of Health, Rome, Italy

Lucio Crinò

“Santa Maria Della Misericordia” Hospital, Perugia, Italy

Maurizio D’Incalci

“Mario Negri” Institute for Pharmacological Research,
Milan, Italy

Riccardo Dalla Favera

Institute for Cancer Genetics, Columbia University,
New York, NY, USA

Giuseppe De Rosa

“Federico II” University of Naples, Italy

Yves A. De Clerck

Children’s Hospital, Los Angeles, CA, USA

Riccardo Dolcetti

CRO-IRCCS, National Cancer Institute, Aviano,
Pordenone, Italy

Manuela Ferracin

University of Ferrara, Italy

Margaret Foti

AACR - American Association for Cancer Research,
Philadelphia, PA, USA

Jonathan A. Fletcher

Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA, USA

Alfredo Fusco

Institute of Endocrinology and Experimental Oncology,
CNR, Naples, Italy

Chiara Gabellini

Regina Elena National Cancer Institute, Rome, Italy

Gianluca Gaidano

“Amedeo Avogadro” University of Eastern Piedmont,
Novara, Italy

Cecilia Garofalo

IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy

Raffaella Giavazzi

“Mario Negri” Institute for Pharmacological Research,
Milan, Italy

Silvia Giordano

Institute for Cancer Research and Treatment,
University of Turin, Candiolo, Italy

Anna R. Giuliano

Moffitt Cancer Center & Research Institute,
Tampa, FL, USA

Sandro Grilli

University of Bologna, Italy

Guido Kroemer

INSERM, Institute Gustave Roussy, Villejuif, France

Pier-Luigi Lollini

University of Bologna

Domenica Mangieri

University Hospital of Parma, Italy

Antonio Marchetti

*Center of Predictive Molecular Medicine,
University-Foundation, Chieti, Italy*

Seamus J. Martin

*Smurfit Institute of Genetics, Trinity College,
Dublin, Ireland*

Maria G. Masucci

Karolinska Institute, Stockholm, Sweden

Francesco Nicassio

IFOM-IEO Campus, Milan, Italy

Nicola Normanno

"G. Pascale" National Cancer Institute, Naples, Italy

Moshe Oren

Weizmann Institute, Rehovot, Israel

Pierlorenzo Pallante

*Institute of Endocrinology and Experimental Oncology,
CNR, Naples, Italy*

Ugo Pastorino

IRCCS National Cancer Institute, Milan, Italy

Salvatore Pece

IFOM-IEO Campus, Milan, Italy

Andrea Pession

University of Bologna, Italy

Piero Picci

IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy

Stefano A. Pileri

University of Bologna, Italy

Carmine Pinto

S. Orsola-Malpighi Hospital, Bologna, Italy

Carola Ponzetto

University of Turin, Italy

Janusz Rak

*McGill University, Children's Hospital Research Institute,
Montreal, Quebec, Canada*

Katia Scotlandi

IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy

Samantha Solito

University of Padua, Italy

Gabriella Sozzi

IRCCS National Cancer Institute, Milan, Italy

Stefania Tommasi

"Giovanni Paolo II" National Cancer Institute, Bari, Italy

Daniela Trisciuoglio

Regina Elena National Cancer Institute, Rome, Italy

Giuseppe Viglietto

University of "Magna Graecia", Catanzaro, Italy

Rosa Visone

University of Chieti, Italy

Laurence Zitvogel

INSERM, Institute Gustave Roussy, Villejuif, France

PROGRAMME AT A GLANCE

MONDAY, OCTOBER 1ST

11.30 - 13.30	Pre-meeting SIC young investigators
13.30 - 18.30	Registration and poster hanging
14.30 - 15.30	Opening ceremony
15.30 - 16.30	Opening lecture
16.30 - 18.30	Recent advances in translational research: new opportunities in rare diseases
19.00	Welcome cocktail (Monumental Area of Rizzoli Institute)

TUESDAY, OCTOBER 2ND

08.30 - 18.30	Registration and poster hanging
09.00 - 10.15	Controversies in basic cancer research
10.15 - 10.45	Coffee break
10.45 - 12.30	Controversies in basic cancer research
12.45 - 13.30	Poster viewing with aperitif "Lambrusco e Grana Padano"
13.30 - 14.30	Lunch
14.30 - 15.30	"Giorgio Prodi" Lecture
15.30 - 16.15	Highlights in personalized medicine (Joint meeting SIC-AIOM)
16.15 - 16.45	Coffee break
16.45 - 18.30	Highlights in personalized medicine (Joint meeting SIC-AIOM)
18.30 - 19.30	Young Investigators Meeting

WEDNESDAY, OCTOBER 3RD

08.30 - 18.30	Registration
09.00 - 11.00	Environment and cancer prevention
11.00 - 11.30	Coffee break
11.30 - 12.45	Translational perspectives of next-generation sequencing
12.45 - 13.30	Poster viewing with aperitif "Albana e Mortadella"
13.30 - 14.30	Lunch
14.30 - 17.30	Poster discussions (4 sessions) - From 16.00 to 18.00 open coffee
17.30 - 19.00	New frontiers in cancer biology
19.00 - 19.45	SIC General Assembly
20.30	Social Event (Circolo Ufficiali, Palazzo Grassi - via Marsala, 12 - Bologna)

THURSDAY, OCTOBER 4TH

09.00 - 11.00	Drug resistance: new players
11.00 - 11.20	Coffee break
11.20 - 11.30	Greetings from EACR
11.30 - 12.15	Award ceremony
12.15 - 13.15	Closing lecture
13.15 - 13.30	Closing remarks

SCIENTIFIC PROGRAMME





MONDAY, OCTOBER 1st

11.30 – 13.30 **PRE-MEETING SIC YOUNG INVESTIGATORS**

Chairs: Chiara Gabellini (Rome, Italy), Pierlorenzo Pallante (Naples, Italy)

**Young researchers grow up: funding opportunities and grant proposal writing
Round table with grant reviewers and young investigator grant winners**

Participants:

Manuela Ferracin (*Ferrara, Italy*)

Silvia Giordano (*Turin, Italy*)

Domenica Mangieri (*Parma, Italy*)

Gabriella Sozzi (*Milan, Italy*)

Rosa Visone (*Chieti, Italy*)

MONDAY, OCTOBER 1st

13.30 – 18.30 Registration and poster hanging

14.30 – 15.30 **OPENING CEREMONY**

Chairs: Guido Biasco (Bologna, Italy), Katia Scotlandi (Bologna, Italy)

Greetings from the Authorities

Greetings from AACR

Margaret Foti (*American Association for Cancer Research, Philadelphia, USA*)

The Rizzoli Institute: from monastery to research Institute

Piero Picci (*Bologna, Italy*)

15.30 – 16.30 **OPENING LECTURE**

Chair: Riccardo Dolcetti (Aviano PN, Italy)

The genome of cancer cells: lessons from B-cell lymphoma

Riccardo Dalla Favera (*New York, USA*)

16.30 – 18.30 **RECENT ADVANCES IN TRANSLATIONAL RESEARCH: NEW OPPORTUNITIES IN RARE DISEASES**

Chairs: Andrea Pession (Bologna, Italy), Piero Picci (Bologna, Italy)

16.30 – 17.00 **Can translational research contribute to change peripheral T-cell lymphomas into curable diseases?**

Stefano A. Pileri (*Bologna, Italy*)

17.00 – 17.15 **Pezcoller Foundation fellowship 2011-2012 winner award**

Harnessing reactive oxygen species to target cancer cells

M. Silic-Benussi, M. Manicone, I. Cavallari, L. Chieco-Bianchi, S. Indraccolo, DM. D'Agostino, V. Ciminale

Department of Surgical Science, Oncology and Gastroenterology, University of Padua, Padua, Italy

F7

17.15 – 17.45 **Differentiation therapy for solid tumors? The rhabdomyosarcoma case**

Carola Ponzetto (*Turin, Italy*)

17.45 – 18.00 **MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin**

M. Ferracin, M. Pedriali, A. Veronese, R. Gafà, E. Magri, CM. Croce, G. Lanza, P. Querzoli, M. Negrini

Department of Experimental and Diagnostic Medicine, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy

Q2

18.00 – 18.30 **Lessons from gastrointestinal stromal tumors**

Jonathan A. Fletcher (*Boston, USA*)

19.00 **WELCOME COCKTAIL (Monumental Area of Rizzoli Institute)**

TUESDAY, OCTOBER 2nd

08.30 – 18.30 Registration and poster hanging

09.00 – 12.30 **CONTROVERSIES IN BASIC CANCER RESEARCH**

Chairs: Alfredo Fusco (Naples, Italy), Silvia Giordano (Turin, Italy)

09.00 – 09.30 **Autophagy in response to cancer therapy: a two-edged sword**
Guido Kroemer (*Villejuif, France*)

09.30 – 09.45 **Ras and p53 cooperate to induce a non-conventional mechanism of cell death upon triggering of CD99 by monoclonal antibodies in Ewing sarcoma**
C. Guerzoni, M. Terracciano, MC. Manara, M. Sciandra, G. Bernard, F. Moretti, N. Zini, AM. Porcelli, M. Rugolo, P. Picci, K. Scotlandi.
Laboratory of Experimental Oncology, Prometeo Laboratory, STB, RIT Department, Rizzoli Orthopaedic Institute, Bologna, Italy

AI

09.45 – 10.15 **Oncogene-induced cell death**
Seamus J. Martin (*Dublin, Ireland*)

10.15 – 10.45 *Coffee break*

10.45 – 11.15 **Controversies in tumor immunology: immunogenic cell death and immune biomarkers**
Laurence Zitvogel (*Villejuif, France*)

11.15 – 11.30 **Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers**
A. Rigoni, C. Tripodo, S. Piconese, G. Mauri, M. Parenza, S. Sangaletti, MP. Colombo, P. Pittoni
Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, IRCCS National Cancer Institute, Milan, Italy

V4

11.30 – 12.00 **Oncogenes and microvesicles in cancer progression**
Janusz Rak (*Montreal, Canada*)

12.00 – 12.15 **Fractalkine ligand - receptor axis dictates prognostic outcome in human colorectal cancer**
M. Erreni, F. Grizzi, I. Siddiqui, F. Marchesi, S. Pesce, D. Morone, G. Celesti, A. Doni, P. Bianchi, L. Laghi, A. Mantovani, P. Allavena
Department of Immunology and Inflammation, IRCCS Humanitas Clinical Institute, Rozzano, Milan, Italy

Z12

12.15 – 12.30 **CD34+ adipose tissue cells increase breast cancer cell motility and invasion**
S. Orecchioni, G. Gregato, G. Talarico, C. Aldeni, S. Barozzi, I. Martin-Padura, F. Bertolini
Laboratory Unit of Clinical Haematology-Oncology, European Institute of Oncology, Milan, Italy

E10

12.45 – 13.30 **POSTER VIEWING WITH APERITIF “LAMBRUSCO E GRANA PADANO”**

13.30 – 14.30 *Lunch*

TUESDAY, OCTOBER 2nd

14.30 – 15.30 “GIORGIO PRODI” LECTURE

Introduction: Riccardo Dolcetti (Aviano PN, Italy)

Angiogenesis inhibitors: enthusiasm and disappointment

Raffaella Giavazzi (Milan, Italy)

15.30 – 18.30 HIGHLIGHTS IN PERSONALIZED MEDICINE (Joint meeting SIC-AIOM)

Chairs: Nicola Normanno (Naples, Italy), Carmine Pinto (Bologna, Italy)

15.30 – 16.00 **Impact of circulating miRNA on personalized lung cancer management**

Ugo Pastorino (Milan, Italy)

16.00 – 16.15 **Dual origin of circulating microRNAs**

MJ. Marzi, PP. Di Fiore, F. Nicassio

Department of Experimental Oncology - IEO, European Institute of Oncology, Center for Genomic Science of IIT@SEMM, Italian Institute of Technology, IFOM-IEO Campus, Milan, Italy

Q29

16.15 – 16.45 *Coffee break*

16.45 – 17.15 **Personalized medicine in lung cancer**

Lucio Crinò (Perugia, Italy)

17.15 – 17.30 **Monoclonal antibodies against ErbB3 inhibit growth and migration of human melanoma cells: effects on receptor internalization, recycling and degradation**

L. Fattore, E. Marra, F. Belleudi, F. Mazzetta, MR. Giovagnoli, R. Mancini, L. Aurisicchio, MR. Torrisi, G. Ciliberto

Pasteur Institute-Cenci Bolognetti Foundation, Department of Molecular and Clinical Medicine, Sapienza University of Rome, Rome, Italy

S6

17.30 – 18.00 **Molecular basis and novel options for alternative epigenetic treatments against cancer**

Lucia Altucci (Naples, Italy)

18.00 – 18.30 *Lecture sponsored by PharmaMar*

The importance of translational research in drug development. The example of trabectedin

Maurizio D'Incalci (Milan, Italy)

18.30 – 19.30 YOUNG INVESTIGATORS MEETING



WEDNESDAY, OCTOBER 3rd

08.30 – 18.30 Registration

09.00 – 11.00 ENVIRONMENT AND CANCER PREVENTION

Chairs: Riccardo Dolcetti (Aviano PN, Italy), Sandro Grilli (Bologna, Italy)

09.00 – 09.30 **Detection of cancer risk in polluted sites and adoption of prevention strategies**
Pietro Comba (Rome, Italy)

09.30 – 10.00 **Regulatory assessment of the cancer potential of chemicals in food**
Fernando Aguilar (Maisons-Alfort Cedex, France)

10.00 – 10.30 **HPV epidemiology and the prevention of cancer in men**
Anna R. Giuliano (Tampa, Florida, USA)

10.30 – 11.00 **Molecular mechanisms of viral oncogenesis - the lesson of Epstein-Barr virus**
Maria G. Masucci (Stockholm, Sweden)

11.00 – 11.30 *Coffee break*

11.30 – 12.45 TRANSLATIONAL PERSPECTIVES OF NEXT-GENERATION SEQUENCING

Chairs: Guido Biasco (Bologna, Italy), Stefano A. Pileri (Bologna, Italy)

11.30 – 12.00 **Genomic complexity of chronic lymphocytic leukemia: pathogenetic and clinical implications**
Gianluca Gaidano (Novara, Italy)

12.00 – 12.15 **Towards a functional melanoma classification by phosphoproteomics profiling** **N14**
I. Penna, A. Molla, C. Vegetti, I. Bersani, R. Mortarini, A. Anichini
Human Tumors Immunobiology Unit, Dept. of Experimental Oncology and Molecular Medicine, IRCCS National Cancer Institute, Milan, Italy

12.15 – 12.45 **Lecture sponsored by Roche Diagnostic**
Using next generation sequencing for guiding therapies in solid tumors
Antonio Marchetti (Chieti, Italy)

12.45 – 13.30 POSTER VIEWING WITH APERITIF “ALBANA E MORTADELLA”

13.30 – 14.30 *Lunch*

14.30 – 17.30 PARALLEL POSTER DISCUSSIONS

WEDNESDAY, OCTOBER 3rd

14.30 – 16.00 Poster Discussion I - Sala Congressi Anfiteatro TUMOR IMMUNOLOGY AND MICROENVIRONMENT Chairs: Anna Bagnato (Rome, Italy), Samantha Solito (Padua, Italy)

Anti-tumor activity of CPG oligonucleotides aerosolization in mouse models of lung metastases
L. Sfondrini, M. Tortoreto, M. Sommariva, A. Meini, S. Piconese, N. Van Rooijen, N. Zaffaroni, E. Tagliabue, A. Balsari
Department of Biomedical Sciences for Health, University of Milan, Italy

V9

Self and xenogeneic variants of HER2 differently affect cytokines-pattern of T cells: considerations for designing tumor vaccines
S. Occhipinti, L. Sponton, C. Caorsi, A. Amici, C. Marchini, E. Quagliano, A. Novarino, M. Donadio, L. Ciuffreda, A. Sapino, F. Novelli, M. Giovarelli
Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy

VI3

Dissecting the role of transcription factors C/EBP β and STAT3 in MDSC-mediated immune suppression
L. Pinton, S. Solito, L. Perilli, N. Sonda, V. Damuzzo, D. Oro, A. Anselmi, S. Francescato, P. Zanovello, V. Bronte, S. Mandruzzato
Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padua, Padua, Italy

VI5

IGKV3 proteins as candidate “off-the-shelf” vaccines for kappa-light chain-restricted B cell non-Hodgkin’s lymphomas
D. Martorelli, E. Muraro, V. De Re, R. Turrini, E. Pasini, L. Romagnoli, R. Mortarini, L. Surdo, A. Rosato, A. Anichini, R. Dolcetti
Cancer Bio-Immunotherapy Unit and C.R.O., IRCCS – National Cancer Institute, Aviano, PN, Italy

VI9

Normal mammary cells influence the growth of cancer cells through ER and PI3K/AKT/mTOR pathway: understanding the role of microenvironment in breast cancer
M. Riverso, A. Kortenkamp, E. Silva
UCL School of Pharmacy, University of London, London, United Kingdom

S10

Bone marrow stroma CD40 expression in splenic marginal zone lymphoma is associated with prominent mast cell infiltration and correlates with shorter time to progression
C. Guarnotta, G. Franco, B. Frossi, S. Sangaletti, M. Calvaruso, Al. Gulino, S. Buffa, C. Pucillo, AM. Florena, L. Arcaini, MP. Colombo, C. Tripodo
Science Department for the Promotion of Health, University of Palermo, Palermo, Italy

Z8

The role of matricellular proteins in osteosarcoma tumor progression
I. Torselli, M. Parenza, C. Tripodo, K. Scotlandi, MP. Colombo, C. Chiodoni
Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, National Cancer Institute, IRCCS Foundation, Milan, Italy

Z10

Involvement of BH4 domain and intra-cellular localization of BCL-2 protein in the modulation of pro-angiogenic HIF-1/VEGF axis in melanoma cells under hypoxic condition
C. Gabellini, T. De Luca, D. Trisciuglio, M. Desideri, M. Biffoni, D. Del Bufalo
Experimental Chemotherapy Laboratory, Regina Elena National Cancer Institute, Rome, Italy

Z1

Targeting HIF-1-induced COX2/PGE2 pathway in HIPK2 Knockdown cells correlates with dendritic cell activation
A. Garufi, G. Pistrutto, C. Ceci, L. Di Renzo, R. Santarelli, A. Faggioni, M. Cirone, G. D’Orazi
Department of Experimental Oncology, Molecular Oncogenesis Laboratory, “Regina Elena” Cancer Institute, Rome, Italy

Z6

WEDNESDAY, OCTOBER 3rd

14.30 – 16.00 Poster Discussion 2 - Sala Plenaria

CANCER GENETICS

Chairs: Francesco Nicassio (Milan, Italy), Gabriella Sozzi (Milan, Italy)

GenomeCruzer: a tool for integrative 3D visualization and analysis of TCGA datasets

T4

A. Bertotti, C. Isella, L. Vezzadini, R. Corsi, E. Medico

Department of Oncological Sciences, University of Turin Medical School, Candiolo, Turin, Italy

Regulation of the breast cancer cell miRNome by estrogen receptor Beta

S12

M. Ravo, R. Tarallo, G. Nassa, G. Giurato Giorgio, A. Rinaldi, MR. De Filippo, C. Stellato, G. Bruno, E. Nola, A. Weisz

Laboratory of Molecular Medicine and Genomics, University of Salerno, Baronissi, Italy

Silencing of HMGA1 expression inhibits self-renewal and reduces the symmetric/asymmetric division ratio of colon cancer stem cells, likely by upregulating p53 expression

D1

S. Battista, F. Puca, M. Colamaio, A. Fusco

Institute of Endocrinology and Experimental Oncology of CNR - Department of Molecular and Cellular Biology and Pathology, Faculty of Medicine and Surgery, University of Naples "Federico II", Naples, Italy

CDK12 is a novel oncogene with clinical and pathogenetical relevance in breast cancer

Q26

A. Tagliatela, M. Vecchi, D. Tosoni, I. Colaluca, M. Cozzoli, B. Giulini, S. Pece, PP. Di Fiore

IFOM, FIRC Foundation Institute of Molecular Oncology, Milan, Italy

Integrated transcriptome/miRNome analysis reveals step-by-step differences in an animal model of liver carcinogenesis recapitulating human HCC

G6

A. Petrelli, A. Perra, D. Cora', P. Sulas, S. Menegon, C. Manca, C. Migliore, GM. Ledda-Columbano, S. Giordano, A. Columbano

Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy

Δ16HER2 splice variant: a potential master regulator of HER2-driven mammary tumor aggressiveness

Q14

V. Ciravolo, G. Marzano, L. Castagnoli, GC. Ghedini, R. Zappasodi, G. Santilli, A. Palladini, A. Lamolinara, P. Nanni, SM. Pupa

Molecular Targeting Unit, National Cancer Institute, Foundation IRCCS, Milan, Italy

The designed peptide HXR9 controls the MIR-221&222-c-FOS pathway interfering with its HOXB7/PBX2-dependent activation

SI

MC. Errico, F. Felicetti, L. Bottero, A. Boe, N. Felli, G. Mattia, M. Petrini, M. Bellenghi, HS. Pandha, R. Morgan, A. Carè

Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore Sanità, Rome, Italy

Detection of the epidermal growth factor mutations in circulating tumor cells

Q11

R. Pasquale, S. Bevilacqua, C. Roma, AM. Rachiglio, C. Esposito, F. Fenizia, ML. La Porta, P. Carotenuto, A. De Luca, C. Cacciapuoti, N. Normanno

Cell Biology and Biotherapy Unit, INT "Pascale Foundation", Naples, Italy

Gene expression profile supports classification of undifferentiated pleomorphic sarcomas

Q6

E. Pivetta, B. Wassermann, L. Del Bel Belluz, TME. Modica, V. Canzonieri, A. Colombatti, P. Spessotto

Experimental Oncology 2, CRO, IRCCS, National Cancer Institute, Aviano (PN), Italy

WEDNESDAY, OCTOBER 3rd

16.00 – 17.30 Poster Discussion 3 - Sala Congressi Anfiteatro CANCER DEVELOPMENT AND PROGRESSION

Chairs: Daniela Trisciuglio (Rome, Italy), Giuseppe Viglietto (Catanzaro, Italy)

miR-205 regulates basement membrane deposition in human prostate: implications for cancer development

V. Profumo, P. Gandellini, A. Casamichele, N. Fenderico, S. Borrelli, G. Petrovich, M. Callari, M. Colecchia, R. Mantovani, N. Zaffaroni

Department of Experimental Oncology, IRCCS National Cancer Institute Milan, Italy

G4

miR-205 down-regulation: a key role for epithelial mesenchymal transition and progression of prostate cancer

P. Gandellini, E. Giannoni, ML. Taddei, A. Casamichele, N. Zaffaroni, P. Chiarugi

Department of Biochemical Sciences, University of Florence, Italy

Z22

miR-100 level regulates cancer stem cell differentiation and renders basal-like cells responsive to anti-hormonal therapy

A. Petrelli, F. Iovino, M. Cargnelutti, R. Carollo, M. Callari, G. Santilli, D. Cimino, D. Taverna, F. Montemurro, G. Stassi, S. Giordano

Institute for Cancer Research and Treatment, Division Molecular Oncology, Candiolo, Turin, Italy

D2

A new cell culture model allows the recovery and functional characterization of new cell culture model allows the recovery and functional characterization of disseminated CD133+/CXCR4+/EPCAM- lung cancer initiating cells

G. Bertolini, M. Moro, M. Tortoreto, R. Caserini, U. Pastorino, L. Roz, G. Sozzi

National Cancer Institute, Foundation IRCCS, Milan, Italy

D13

Breast cancer initiating cells: oncoantigen identification and sensitivity to cytotoxic cells

S. Lanzardo, L. Conti, M. Arigoni, D. Cantarella, R. Talerico, E. Carbone, RA. Calogero, F. Cavallo

Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

V20

Functional studies for the dissection of the role of S100A11 in thyroid carcinogenesis

MC. Anania, MP. Riontino, C. Miranda, L. Cleris, G. Manenti, A. Greco

Molecular Mechanisms Unit, IRCCS National Cancer Institute, Milan, Italy

B11

Protumor activities of CDKN1A/P21CIP1 and CDKN2A in a mouse model of embryonal rhabdomyosarcoma

ML. Ianzano, S. Croci, G. Nicoletti, A. Palladini, L. Landuzzi, V. Grosso, I. Santeramo, M. Urbini, M. Dall'Ora, D. Ranieri, C. De Giovanni, PL. Lollini, P. Nanni

Department of Experimental Pathology, Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Italy

B6

Effects of Hedgehog signaling inhibition by NVP-LDE 225 on tumor growth and invasion of human renal cancer cells

C. D'Amato, R. Rosa, V. D'Amato, V. Damiano, L. Formisano, L. Nappi, R. Marciano, AP. De Maio, S. De Placido, R. Bianco

University of Naples "Federico II" - Department of Endocrinology and Molecular and Clinical Oncology

N7

Dissection of the role of pericytes during early metastatic spread

D. Mangieri, C. Alias, R. Perris

Unit of Pathological Anatomy and Histology, Parma University Hospital, COMT – Centre for Molecular and Translational Oncology, University of Parma, Parma, Italy

E14

WEDNESDAY, OCTOBER 3rd

16.00 – 17.30 Poster Discussion 4 - Sala Plenaria BIOMARKERS AND THERAPY

Chairs: Cecilia Garofalo (Bologna, Italy), Stefania Tommasi (Bari, Italy)

Single-agent inhibition of checkpoint kinase 1 (CHK1) and 2 (CHK2) by PF-0477736 (PFIZER) in B-acute lymphoblastic leukemia (ALL)

L9

I. Iacobucci, A. Ghelli Luserna Di Rorà, E. Derenzini, E. Imbrogno, A. Ferrari, F. Cattina, S. Pomella, C. Papayannidis, C. Venturi, V. Guadagnuolo, A. Lonetti, MV. Verga Falzacappa, E. Ottaviani, MC. Abbenante, S. Soverini, D. Russo, PG. Pellicci, M. Baccarani, G. Martinelli
Department of Hematology/Oncology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy

Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence

N23

MT. Di Martino, E. Leone, N. Amodio, U. Foresta, M. Lionetti, MR. Pitari, ME. Gallo Cantafio, A. Gullà, F. Conforti, E. Morelli, V. Tomaino, M. Rossi, M. Negrini, M. Ferrarini, M. Caraglia, MA. Shammas, NC. Munshi, KC. Anderson, A. Neri, P. Tagliaferri, P. Tassone
Department of Experimental and Clinical Medicine, "Magna Graecia" University and Medical Oncology Unit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy

Modulation in tumor cells of Micro-RNAs involved in sensitivity to chemotherapy after CpG-ODN treatment

H2

M. Berardi, L. De Cecco, M. Sommariva, A. Meini, E. Tagliabue, A. Balsari
Molecular Targeting Unit, Department of Experimental Oncology, National Cancer Institute, Foundation IRCCS, Milan, Italy

Base excision repair in breast cancer: new markers or new molecular targets?

B8

S. De Summa, R. Pinto, B. Pilato, D. Petriella, K. Danza, P. Petrillo, E. Foglia Manzillo, S. Tommasi, A. Paradiso
Molecular Genetics Laboratory, "Giovanni Paolo II" National Cancer Centre, Bari, Italy

Serine protease inhibitor SERPINB5 impacts cancer cell sensitivity to chemotherapy

Q10

T. Triulzi, M. Ratti, M. Tortoreto, P. Aiello, C. Ghirelli, ML. Carcangiu, P. Casalini, E. Tagliabue
Molecular Targeting Unit, National Cancer Institute, Foundation IRCCS, Milan, Italy

Zoledronic acid delivered by self-assembly pegylated nanoparticles has antitumor efficacy against glioblastoma cell lines and xenografts

R3

M. Porru, S. Zappavigna, A. Luce, A. Panico, G. Salzano, S. Lusa, G. De Rosa, C. Leonetti, M. Caraglia
Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy

Characterization of Zoledronic acid resistance developed in prostate cancer cells

L8

MR. Milone, B. Pucci, F. Bruzzese, S. Costantini, F. Capone, A. Budillon
Mercogliano Oncology Research Center (CROM), Mercogliano (AV), Italy

Effects of dual PI3K and mTOR inhibition on incidence and local growth of prostate cancer bone metastases

N21

GL. Gravina, A. Mancini, N. Rucci, C. Liang, M. Capulli, J. Gibbons, A. D'Alessandro, V. Tombolini, AM. Teti, A. Lenzi, EA. Jannini, C. Festuccia
Department of Experimental Medicine, "La Sapienza" University of Rome, Rome, Italy

Liquid biopsy: a blood based non-invasive approach to monitor acquired resistance to targeted therapies

B5

G. Siravegna, E. Scala, E. Valtorta, R. Schiavo, K. Bencardino, S. Veronese, A. Sartore-Bianchi, M. Gambacorta, A. Cassingena, F. Di Nicolantonio, S. Siena, A. Bardelli
Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment (IRCC), Candiolo, Turin, Italy

WEDNESDAY, OCTOBER 3rd

16.00 – 18.00 *Coffee break*

17.30 – 19.00 NEW FRONTIERS IN CANCER BIOLOGY

Chairs: Pier-Luigi Lollini (Bologna, Italy), Salvatore Pece (Milan, Italy)

17.30 – 18.00 **The impact of nanotechnologies in cancer treatments**
Giuseppe De Rosa (Naples, Italy)

18.00 – 18.30 **The extracellular matrix embraces cancer and immunity**
Mario P. Colombo (Milan, Italy)

18.30 – 19.00 **Insulin and insulin receptor in cancer: problems and new opportunities**
Antonino Belfiore (Catanzaro, Italy)

19.00 – 19.45 SIC GENERAL ASSEMBLY

20.30 SOCIAL EVENT (Palazzo Grassi)

THURSDAY, OCTOBER 4th

09.00 – 11.00 DRUG RESISTANCE: NEW PLAYERS

Chairs: Alfredo Budillon (Naples, Italy), Maurizio D'Incalci (Milan, Italy)

09.00 – 09.30 Control of drug resistance by the tumor microenvironment

Yves A. De Clerck (Los Angeles, USA)

09.30 – 09.45 Epigenetic regulation of EMT-related factors is related to chemoresistance through endothelin A receptor signalling in ovarian cancer cells

L. Rosanò, R. Cianfrocca, P. Tocci, E. Semprucci, F. Spinella, V. Di Castro, PG. Natali, A. Bagnato

Laboratory of Molecular Pathology, Regina Elena National Cancer Institute, Rome, Italy

L5

09.45 – 10.15 Molecular mechanisms of resistance to anti EGFR therapies in colorectal cancers

Alberto Bardelli (Turin, Italy)

10.15 – 10.30 UBCH10 modulates the response to EGFR-TKI treatment in NSCLC cells

P. Pallante, U. Malapelle, R. Sepe, G. Troncone, A. Fusco

Institute for Experimental Endocrinology and Oncology - CNR, c/o Department of Molecular and Cellular Biology and Pathology, University of Naples "Federico II", Naples, Italy

N10

10.30 – 11.00 Functional genomic screening unveils new players in platinum resistance

Gustavo Baldassarre (Aviano, Italy)

11.00 – 11.20 Coffee break

11.20 – 11.30 Greetings from EACR

Moshe Oren (European Association for Cancer Research, Rehovot, Israel)

11.30 – 12.15 AWARD CEREMONY

Chairs: Riccardo Dolcetti (Aviano PN, Italy), Silvia Giordano (Turin, Italy)

- "Piero Trivella" and EACR Awards for the best posters
- "Elena Cappannini" Award for the best 2011 publication
- "Pezcoller Foundation - Ferruccio and Elena Bernardi" scholarship Award
- Travel Grants

12.15 – 13.15 CLOSING LECTURE

Chair: Riccardo Dolcetti (Aviano PN, Italy)

Exploring the links between p53 and cancer: lessons and challenges

Moshe Oren (Rehovot, Israel) - *Sponsored by EACR*

13.15 – 13.30 CLOSING REMARKS

INFORMATION





GENERAL INFORMATION

DATES

Bologna, Monday 1st - Thursday 4th, October 2012

MEETING VENUE

Istituto Ortopedico Rizzoli

Centro di Ricerca Codivilla-Putti

Via di Barbiano, 1/10 - 40136 Bologna, Italy

www.ior.it

SIC SECRETARIAT

Società Italiana di Cancerologia

Via G. Venezian, 1 - 20133 Milan, Italy

Phone +39 02 2666895 - Fax +39 02 2664342

E-mail: sic@istitutotumori.mi.it

www.cancerologia.it

ORGANIZING SECRETARIAT

Studio E.R. Congressi - Triumph Group

Via Marconi, 36 - 40122 Bologna, Italy

Phone +39 051 4210559 - Fax +39 051 4210174

E-mail: ercongressi@triumphgroup.it

www.ercongressi.it

LANGUAGE

The official language of the Meeting is English. Simultaneous translation will not be provided.

SLIDES

Slides must be in English. Computer videoprojection will be available in Power Point.

Special requirements should be communicated to the Organizing Secretariat as soon as possible.

Power-Point presentations should be handed to the slide centre one hour before the beginning of the session.

BADGE

Participants are kindly requested to wear their badge throughout the Meeting.

ATTENDANCE CERTIFICATE

A certificate will be given to all participants at the end of the Meeting.

EXHIBITION AND SPONSORSHIP

A technical, pharmaceutical and public exhibition will take place in the Meeting Venue throughout the scientific workshop. For any information, please contact the Organizing Secretariat Studio ER Congressi - Triumph Group.

REGISTRATION

The registration fee includes:

- Conference kit
- Participation in the Scientific Sessions
- Attendance Certificate
- Admission to the Opening Ceremony and Welcome Cocktail, coffee breaks, lunches and Social Event.

CANCELLATION

In case of cancellation, there will be no reimbursement.

INSURANCE

Registration fee does not include insurance of any kind. The Congress Organizers will not be responsible for any participant failing or damages. Any type of insurance should be purchased by congress participants on their own.

SCIENTIFIC INFORMATION

ITALIAN CME CREDITS

9 Italian CME credits are recognized for Biologists, Chemists, Physicians (Haematology, Medical Genetic, Oncology, Clinical Pathology, Pharmacology and Clinical Toxicology).

PRIZES

- “Piero Trivella” and EACR Prizes to the best posters
- “Elena Cappannini” Prize to the best 2011 publication as first author in innovative approaches for cancer treatments
- Scholarship “Pezcoller Foundation - Ferruccio and Elena Bernardi”
- Travel Grants

All prizes will be awarded, on the basis of a merit ranking, on October 4th, 2012 during the Award Ceremony.

SOCIAL EVENTS

MONDAY, OCTOBER 1st

19.00 Welcome Cocktail - Monumental Area of Rizzoli Institute

Via Pupilli, 1 - Bologna

WEDNESDAY, OCTOBER 3rd

20.30 Social Dinner - Circolo Ufficiali, Palazzo Grassi

Via Marsala, 12 - Bologna

PRACTICAL INFORMATION

TOURIST INFORMATION

For all events and cultural initiatives that take place in Bologna, you can visit the official tourism website of the Municipality of Bologna: www.bolognawelcome.com



HOW TO REACH THE MEETING VENUE

The **Istituto di Ricerca Codivilla-Putti Congress Centre** is located in Via di Barbiano 1/10. Please find here some useful information.

By road: for the Istituto di Ricerca Codivilla-Putti Congress Centre follow the signs for the Poliambulatorio Rizzoli: when you get to Porta Castiglione on the avenues, go southwards (away from the city - towards the hills) along via Castiglione, which then becomes via di Barbiano, a narrow road.

The entrance to the pay car park of the Rizzoli Codivilla-Putti Congress Centre is at the Poliambulatorio entrance.


By bus*: bus “A” connects the town centre with the Istituto di Ricerca Codivilla-Putti Congress Centre. It runs every 10-11 minutes (depending on the time of day) and takes about 22 minutes to complete the journey. On board there is a ticket machine.

By rail: bus “A” connects also the railway station with the Istituto di Ricerca Codivilla-Putti Congress Centre. It runs every 10-11 minutes (depending on the time of day) and takes about 22 minutes to complete the journey. On board there is a ticket machine.

By air: the “BLQ” bus connects G. Marconi airport with Bologna railway station. It runs every 15 minutes and takes 30 minutes to get to the station. From the station you can catch bus “A” as described above.

**Please note:*

Bus “A” will not be running on October 4th because Bologna celebrates its Patron Saint, San Petronio.



Hotels

- | | | |
|---|--|--|
| 1 Palace Hotel
Via Monte Grappa, 9/2 | 5 Millennhotel
Via Cesare Boldrini, 4 | 9 Hotel Tre Vecchi
Via dell'Indipendenza, 47 |
| 2 Foresteria S. Giovanni in Monte
Via De' Chiari, 8 | 6 Hotel Regina
Via dell'Indipendenza, 51 | 10 Hotel Holiday
Via Bertiera, 13 |
| 3 Albergo Centrale
Via della Zecca, 2 | 7 Hotel Europa
Via Cesare Boldrini, 11 | |
| 4 Astoria
Via Fratelli Rosselli, 14 | 8 Hotel Re Enzo
Via Santa Croce, 26 | |

Shuttle meeting points (Times will be provided at the conference and in every hotel)

- | | |
|--|-----------------------------|
| A Via Amendola cross Via Milazzo | C Via dell'Indipendenza, 44 |
| B Via San Felice cross Via della Grada | D Piazza Malpighi |
| | E Via Santo Stefano, 40 |

Social Events

- | |
|---|
| F Welcome Cocktail
Rizzoli Institute |
| G Social Dinner
Palazzo Grassi |

REGISTRATION FEES (VAT included)

	<i>Late registration by September 26th</i>	<i>On-site registration</i>
SIC MEMBER	€ 410,00	€ 450,00
NON SIC MEMBER	€ 510,00	€ 550,00
SIC MEMBER UNDER 35	€ 260,00	€ 280,00
NON SIC MEMBER UNDER 35	€ 330,00	€ 355,00

DAILY REGISTRATION FEES (VAT included)

	<i>Daily registration October 2 or 3</i>	<i>Daily registration October 1 or 4</i>
SIC MEMBER	€ 150,00	€ 75,00
NON SIC MEMBER	€ 180,00	€ 90,00
SIC MEMBER UNDER 35	€ 100,00	€ 50,00
NON SIC MEMBER UNDER 35	€ 120,00	€ 60,00

The registration fee includes:

- Conference kit
- Participation in the Scientific Sessions
- Attendance Certificate
- Admission to the Opening Ceremony and Welcome Cocktail, coffee breaks, lunches and Social Event

HOW TO REGISTER

The filled registration form and payment are available on line at the website:

www.ercongressi.it/sic/registration.html



I nostri farmaci creano un futuro migliore per tutti.

AstraZeneca è un'azienda biofarmaceutica orientata all'innovazione e focalizzata su scala internazionale nella ricerca, nello sviluppo e nella commercializzazione di farmaci etici.

Il nostro obiettivo è curare alcune delle malattie più serie al mondo attraverso farmaci eccellenti, per migliorare la vita delle persone nel modo più veloce, sicuro ed efficiente.



SOCIETÀ ITALIANA DI CANCEROLOGIA

SAVE THE DATE!

**55th Annual Meeting
of the Italian Cancer Society**

Welcome to the South:
understanding onc-OMICS for
personalizing cancer therapy

Catanzaro, September 2013

Scientific Coordinator

Giuseppe Viglietto

University of "Magna Graecia", Catanzaro, Italy